Radiotherapy for High-Risk Non-Muscle-Invasive Bladder Cancer: Current Evidence and Future Directions
while definitive chemoradiotherapy is a promising option for selected patients, it remains investigational and should be considered only in those who are unfit for or decline radical cystectomy. Prospective randomized studies are needed to better define its role in contemporary management.
Authors
- Anthony D. Nehlsen (ORCID: https://orcid.org/0000-0003-3210-1415)
- Kunal K. Sindhu (ORCID: https://orcid.org/0000-0001-9376-8307)
- Nicholas J. Murphy (ORCID: https://orcid.org/0000-0002-9265-994X)
- Osama Zaytoun (ORCID: https://orcid.org/0000-0001-6930-289X)
- Kristin Hsieh (ORCID: https://orcid.org/0000-0003-4100-473X)
- Lucas Resende Salgado (ORCID: https://orcid.org/0000-0002-0798-1425)
- Anum Aamir
- Ahmed Rabie
- Zachary Dovey
Institutions
- Northwell Health (US)
- Mount Sinai Hospital (US)
- Mount Sinai Medical Center (US)
- Mount Sinai Hospital (US)
- Icahn School of Medicine at Mount Sinai (US)
Publication Details
- Journal
- Current Oncology
- Published
- 2026-04-17
- DOI
- https://doi.org/10.3390/curroncol33040225
- Primary Topic
- Bladder and Urothelial Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00